Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
GENEVA--(BUSINESS WIRE)--Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025.
STAAR Surgical Reiterates Compelling, Premium Cash Value Provided by Alcon Merger
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, i...
Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) b...
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease.
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference
GENEVA--(BUSINESS WIRE)--Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference.
Why Alcon (ALC) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Alcon: Q3, Slight Guidance Cut Is Not Something Structural
I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $118 per share, despite a minor guidance cut. Alcon's new product launches, including PRECISION7 and Systane Pro, are exp...
Alcon cuts 2024 forecasts, as slow US hits surgical unit
Eye-care group Alcon cut its 2024 forecasts and missed market expectations for third-quarter sales on Tuesday evening, as a soft U.S. market hit its surgical business.
Reasons to Retain Alcon Stock in Your Portfolio for Now
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y
Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.
Alcon (ALC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates...
Alcon's (ALC) Market Share Gains, New Launches Aid Growth
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.
Alcon (ALC) Rides on Innovation, Balanced Segmental Sales
Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.
Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H
We have narrowed our search to five Medical Instruments stocks. These are: DXCM, TMO, ISRG, ALC, HOLX.
Alcon (ALC) Inks Buyout Deal to Expand Its Glaucoma Portfolio
Alcon (ALC) announces the closing of its deal to acquire BELKIN Vision. Per the terms of the agreement, Alcon will have access to BELKIN Vision's Direct Selective Laser Trabeculoplasty technology.
Related Companies